Twelve-month outcomes of an ab interno gelatin stent combined with cataract surgery or as a standalone procedure in pseudophakic eyes with open-angle glaucoma.
Rather Peyton A, Vold Steven, McFarland Michael
AI Summary
A gelatin stent for advanced glaucoma effectively lowered eye pressure and reduced medication use, either alone or with cataract surgery, offering a new treatment option.
Abstract
Purpose
To provide safety and effectiveness outcomes at 12 months postsurgery for an ab interno transscleral gelatin stent in patients with advanced refractory glaucoma or intolerant of medical therapy.
Setting
Multisubspecialty ophthalmology practice and surgery center.
Design
Retrospective, single-arm, cohort study.
Methods
All patients implanted with the gelatin stent either combined with cataract surgery or as a solo procedure between February 2017 and April 2018 and meeting eligibility criteria were included. Outcome measures included proportion of patients achieving a 20% reduction in intraocular pressure (IOP), proportions at or below 12 mm Hg, 15 mm Hg, and 18 mm Hg, IOP, medication usage, needling rate, and adverse events.
Results
The study included 92 eyes of 69 patients. Mean preoperative IOP and medications were 16.6 mm Hg on 2.1 medications. Average visual field mean deviation was -13.7 dB. Half (48%) of the patients achieved the primary endpoint of 20% reduction while medication use decreased by -1.7 medications. Most patients at 12 months had IOP of 18 mm Hg or less on zero medications (74%), whereas 34% were medication free and had IOP of 12 mm Hg or less. Bleb needling was required for only 14% of patients. There were few adverse events (13% of eyes), the most common being corrected distance visual acuity loss and hyphema.
Conclusions
Eyes with advanced glaucoma despite maximum tolerated medical therapy achieved lower target IOP on fewer medications after implantation with the gelatin microstent.
MeSH Terms
Shields Classification
Key Concepts6
In a retrospective, single-arm, cohort study of 92 eyes of 69 patients with advanced refractory glaucoma or intolerant of medical therapy, 48% of patients achieved a 20% reduction in intraocular pressure (IOP) at 12 months after implantation with an ab interno transscleral gelatin stent, either combined with cataract surgery or as a solo procedure.
In a retrospective, single-arm, cohort study of 92 eyes of 69 patients with advanced refractory glaucoma or intolerant of medical therapy, medication usage decreased by -1.7 medications at 12 months after implantation with an ab interno transscleral gelatin stent, either combined with cataract surgery or as a solo procedure.
In a retrospective, single-arm, cohort study of 92 eyes of 69 patients with advanced refractory glaucoma or intolerant of medical therapy, 74% of patients had an intraocular pressure (IOP) of 18 mm Hg or less on zero medications at 12 months after implantation with an ab interno transscleral gelatin stent, either combined with cataract surgery or as a solo procedure.
In a retrospective, single-arm, cohort study of 92 eyes of 69 patients with advanced refractory glaucoma or intolerant of medical therapy, 34% of patients were medication free and had an intraocular pressure (IOP) of 12 mm Hg or less at 12 months after implantation with an ab interno transscleral gelatin stent, either combined with cataract surgery or as a solo procedure.
In a retrospective, single-arm, cohort study of 92 eyes of 69 patients with advanced refractory glaucoma or intolerant of medical therapy, bleb needling was required for only 14% of patients at 12 months after implantation with an ab interno transscleral gelatin stent, either combined with cataract surgery or as a solo procedure.
In a retrospective, single-arm, cohort study of 92 eyes of 69 patients with advanced refractory glaucoma or intolerant of medical therapy, few adverse events (13% of eyes) were observed at 12 months after implantation with an ab interno transscleral gelatin stent, either combined with cataract surgery or as a solo procedure, with the most common being corrected distance visual acuity loss and hyphema.
Related Articles5
Five-year outcomes of ab interno Xen 45 gel stent implantation.
Cohort StudyMid-term real world outcomes of the Hydrus ® Microstent in open angle glaucoma.
Case SeriesStandalone XEN45 Gel Stent implantation versus combined XEN45-phacoemulsification in the treatment of open angle glaucoma-a systematic review and meta-analysis.
Systematic ReviewCombined phacoemulsification and trabeculectomy with mitomycin-C.
Case SeriesThree-year canaloplasty outcomes for the treatment of open-angle glaucoma: European study results.
Clinical TrialIs this article assigned to the wrong chapter(s)? Let us know.